FDA Approves SPEVIGO for Generalized Pustular Psoriasis Flares
TUESDAY, Sept. 6, 2022 (HealthDay News) -- The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.
SPEVIGO is a novel, selective antibody infusion that blocks the activation of the interleukin-36 receptor, which is part of an immune system signaling pathway thought to be involved in the cause of GPP. The approval was based on a 12-week trial in which 53 patients with a GPP flare were treated with SPEVIGO or placebo. After one week, more patients treated with SPEVIGO showed no visible pustules than those treated with placebo (54 versus 6 percent).
The most common adverse reactions (≥5 percent) reported in patients taking SPEVIGO were asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection.
“GPP flares can greatly impact a patient’s life and lead to serious, life-threatening complications,” Mark Lebwohl, M.D., lead investigator for the trial, said in a statement. “The approval of SPEVIGO is a turning point for dermatologists and clinicians.”
Approval of SPEVIGO was granted to Boehringer Ingelheim.
Was this page helpful?
Related Posts
Pharmacies, Hospitals Facing Shortage of Asthma Drug Albuterol
THURSDAY, March 9, 2023 (HealthDay News) -- Ongoing shortages of a medication...
La circuncisión: ventajas, desventajas, y lo que los padres deben saber
LUNES, 5 de junio de 2023 (HealthDay News) -- Comprender la circuncisión puede...
Women Have Poorer Survival Than Men After Bypass Surgery
WEDNESDAY, March 8, 2023 (HealthDay News) -- Women are more likely than men to...
American College of Gastroenterology, Oct. 21-26
The annual meeting of the American College of Gastroenterology was held from...